- Trials with a EudraCT protocol (147)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (268)
147 result(s) found for: Ifosfamide.
Displaying page 1 of 8.
EudraCT Number: 2019-003696-19 | Sponsor Protocol Number: E7080-G000-230 | Start Date*: 2020-02-28 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adoles... | |||||||||||||
Medical condition: Relapsed or Refractory Osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) BE (Completed) IE (Completed) NL (Completed) IT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000043-32 | Sponsor Protocol Number: NA | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | |||||||||||||
Full Title: A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract | |||||||||||||
Medical condition: Non-transitional cell carcinoma of the bladder and the urinary tract | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005009-69 | Sponsor Protocol Number: ISG STS 06 01 | Start Date*: 2006-10-06 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY | |||||||||||||
Medical condition: advanced myxoid/round cell liposarcoma pretreated with anthracycline and ifosfamide | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004814-24 | Sponsor Protocol Number: 17SARC04 | Start Date*: 2018-03-19 | |||||||||||
Sponsor Name:INSTITUT CLAUDIUS REGAUD | |||||||||||||
Full Title: Pharmacologic interaction between Ifosfamide and Aprepitant in treated patients with soft tissue sarcoma. | |||||||||||||
Medical condition: Soft tissue sarcoma (localized, local recidive or metastatic) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000052-17 | Sponsor Protocol Number: PK201301 | Start Date*: 2013-10-07 | |||||||||||
Sponsor Name:The Newcastle Upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation | |||||||||||||
Medical condition: Ewing sarcoma patients | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001165-24 | Sponsor Protocol Number: UC-0150/1704 | Start Date*: 2018-06-12 |
Sponsor Name:UNICANCER | ||
Full Title: A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnos... | ||
Medical condition: Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and s... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000719-17 | Sponsor Protocol Number: PIVeR | Start Date*: 2018-03-05 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etop... | |||||||||||||
Medical condition: Patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003930-17 | Sponsor Protocol Number: 1407-GUCG | Start Date*: 2015-10-05 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLO... | |||||||||||||
Medical condition: progressive or recurrent germ cell tumor (measurable or non-measurable) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) SI (Completed) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000259-99 | Sponsor Protocol Number: RG_13-277 | Start Date*: 2014-08-29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Recurrent and refractory Ewing sarcoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) FI (Trial now transitioned) DK (Trial now transitioned) DE (Ongoing) HU (Completed) CZ (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PL (Completed) IT (Trial now transitioned) AT (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000615-84 | Sponsor Protocol Number: OCTO_039 | Start Date*: 2014-11-08 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma | |||||||||||||
Medical condition: Relapsed or metastatic osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001139-31 | Sponsor Protocol Number: STS 2005 14 | Start Date*: 2006-01-27 |
Sponsor Name:Research and Development Directorate, University Hospitals of Leicester NMS Trust | ||
Full Title: European Paediatric Soft Tissue Sarcoma Study Group protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 2005 | ||
Medical condition: Non-rhabdomyosarcoma soft tissue sarcoma. The so called “non-rhabdomyosarcoma” soft tissue sarcomas (NRSTS) account for about 3-4% of paediatric cancers and constitute a very heterogeneous group ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) IT (Ongoing) BE (Completed) IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004762-28 | Sponsor Protocol Number: OsteoREC2015 | Start Date*: 2016-02-25 | |||||||||||
Sponsor Name:ITALIAN SARCOMA GROUP | |||||||||||||
Full Title: Multicentric prospective, randomized, clinical trial for the treatment of patient with relapsed Osteosarcoma (OS) | |||||||||||||
Medical condition: high grade relapsed osteosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006326-48 | Sponsor Protocol Number: CO43810 | Start Date*: 2022-09-27 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AN... | |||||||||||||
Medical condition: CD20 positive B-Cell Non-Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001106-26 | Sponsor Protocol Number: EC11-444-OSTEOSARC | Start Date*: 2012-07-02 |
Sponsor Name:JAVIER MARTÍN BROTO | ||
Full Title: PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA | ||
Medical condition: Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002093-12 | Sponsor Protocol Number: 1506-STBSG | Start Date*: 2017-07-04 | ||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of | ||||||||||||||||||
Full Title: A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastat... | ||||||||||||||||||
Medical condition: Metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) NL (Completed) ES (Completed) LT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016017-24 | Sponsor Protocol Number: 2009-016017-24 | Start Date*: 2010-04-07 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOT... | |||||||||||||
Medical condition: Leiomiosarcomi uterini metastatici o in progressione locale | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000515-24 | Sponsor Protocol Number: RG_17-247 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |||||||||||||
Medical condition: Rhabdomyosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DK (Trial now transitioned) SI (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004251-12 | Sponsor Protocol Number: TOXIPLAT | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Institut Claudius Regaud | |||||||||||||
Full Title: EVALUATION BIOLOGIQUE DE LA TOXICITE RENALE DU CISPLATINE ET DE L’IFOSFAMIDE (TOXIPLAT) | |||||||||||||
Medical condition: pathologies tumorales malignes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001072-13 | Sponsor Protocol Number: GETUG13 | Start Date*: 2005-10-25 |
Sponsor Name:UNICANCER | ||
Full Title: A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206 | ||
Medical condition: Non-Seminoma Germ Cell Tumor | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
Trial protocol: SK (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000242-20 | Sponsor Protocol Number: EURAMOS 1 | Start Date*: 2005-04-05 |
Sponsor Name:SSG | ||
Full Title: A randomised trial of the European and American Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy | ||
Medical condition: Ostesarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) NO (Completed) BE (Completed) IE (Completed) AT (Completed) CZ (Completed) GB (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
